Literature DB >> 29650419

Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer.

Sieske Hoendervangers1, Alice M Couwenberg2, Martijn P W Intven2, Wilhelmina M U van Grevenstein3, Helena M Verkooijen4.   

Abstract

INTRODUCTION: Patients with locally advanced rectal cancer (LARC) who are unfit for chemoradiation (CRT), are often offered short-course radiotherapy followed by delayed surgery (SCRT-delay). This entails a lower radiation dose, no chemotherapy and a shorter treatment period. This may lower their chances for complete tumor response and, as such, organ-sparing approaches. The purpose of this study was to compare the pathological complete response (pCR) rates between neoadjuvant CRT and SCRT-delay in patients with LARC in a nationwide database from the Netherlands.
METHODS: In the population based Netherlands Cancer Registry, clinical stage III rectal cancer patients, diagnosed between 2008 and 2014, who underwent CRT or SCTR-delay were selected. pCR (ypT0N0), near pCR (ypT0-1N0), and tumor and nodal downstaging were compared between the treatment groups using multivariable logistic regression analysis.
RESULTS: 386 patients underwent SCRT-delay and 3659 patients underwent CRT. The pCR-rate in the SCRT-delay group was significantly lower compared to the CRT-group (6.4% vs. 16.2%, p < 0.001). After adjustment for clinical tumor stage, clinical nodal stage and time interval to surgery, SCRT-delay patients were significantly less likely to reach pCR (adjusted odds ratio 0.3, 95%CI 0.2-0.5). Also, near-pCR (ypT0-1N0) as well as tumor and nodal downstaging was observed less often in the SCRT-delay group.
CONCLUSION: Compared to patients treated with neoadjuvant CRT, those receiving SCRT and delayed surgery are less likely to develop pCR. Novel neoadjuvant treatment strategies for patients not fit enough for CRT are needed to increase their eligibility for organ-sparing treatments.
Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Chemoradiation; Locally advanced rectal cancer; Pathological complete response; Short course radiotherapy

Mesh:

Substances:

Year:  2018        PMID: 29650419     DOI: 10.1016/j.ejso.2018.03.014

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

1.  Preoperative short-course radiotherapy (5 × 5 Gy) with delayed surgery versus preoperative long-course radiotherapy for locally resectable rectal cancer: a meta-analysis.

Authors:  Wang Qiaoli; Huang Yongping; Xiong Wei; Xu Guoqiang; Ju Yunhe; Liu Qiuyan; Li Cheng; Guo Mengling; Li Jiayi; Xiong Wei; Yang Yi
Journal:  Int J Colorectal Dis       Date:  2019-11-19       Impact factor: 2.571

Review 2.  Neoadjuvant Short-Course Radiotherapy Followed by Consolidation Chemotherapy before Surgery for Treating Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Chun-Kai Liao; Ya-Ting Kuo; Yueh-Chen Lin; Yih-Jong Chern; Yu-Jen Hsu; Yen-Lin Yu; Jy-Ming Chiang; Pao-Shiu Hsieh; Chien-Yuh Yeh; Jeng-Fu You
Journal:  Curr Oncol       Date:  2022-05-19       Impact factor: 3.109

Review 3.  A Multidisciplinary Approach for the Personalised Non-Operative Management of Elderly and Frail Rectal Cancer Patients Unable to Undergo TME Surgery.

Authors:  Stijn H J Ketelaers; Anne Jacobs; An-Sofie E Verrijssen; Jeltsje S Cnossen; Irene E G van Hellemond; Geert-Jan M Creemers; Ramon-Michel Schreuder; Harm J Scholten; Jip L Tolenaar; Johanne G Bloemen; Harm J T Rutten; Jacobus W A Burger
Journal:  Cancers (Basel)       Date:  2022-05-11       Impact factor: 6.575

Review 4.  Treatment of Rectal Cancer in Older Adults.

Authors:  Ayesha R Sheikh; Hassan Yameen; Kevan Hartshorn
Journal:  Curr Oncol Rep       Date:  2018-11-20       Impact factor: 5.075

Review 5.  Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors.

Authors:  Kasun Wanigasooriya; Robert Tyler; Joao D Barros-Silva; Yashashwi Sinha; Tariq Ismail; Andrew D Beggs
Journal:  Cancers (Basel)       Date:  2020-05-18       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.